Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $68,855.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 293 shares of the company’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $235.00, for a total value of $68,855.00. Following the sale, the insider owned 144,699 shares of the company’s stock, valued at approximately $34,004,265. This represents a 0.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The stock was sold at an average price of $228.95, for a total value of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $198.60, for a total transaction of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $193,858.56.

Natera Stock Down 0.5%

NASDAQ NTRA opened at $241.58 on Friday. The firm has a market cap of $33.42 billion, a PE ratio of -105.49 and a beta of 1.62. The company has a 50 day moving average price of $234.18 and a 200 day moving average price of $191.40. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36.

Natera (NASDAQ:NTRA) last announced its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter last year, the business earned ($0.26) earnings per share. Natera’s revenue was up 34.7% on a year-over-year basis. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Institutional Investors Weigh In On Natera

Institutional investors and hedge funds have recently modified their holdings of the company. Horizon Investments LLC purchased a new stake in Natera in the third quarter valued at approximately $32,000. Hilltop National Bank acquired a new stake in Natera during the 2nd quarter valued at approximately $33,000. Sound Income Strategies LLC boosted its holdings in shares of Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new stake in shares of Natera in the fourth quarter worth $41,000. Finally, Quent Capital LLC acquired a new stake in shares of Natera in the third quarter worth $46,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. TD Cowen reaffirmed a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Thursday. Citigroup assumed coverage on shares of Natera in a report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Finally, Morgan Stanley boosted their target price on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $245.50.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.